Marie D'hooghe, MD, PhD: Pregnancy Plans for Patients With MS
October 4th 2019The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.
Mitsubishi Tanabe Reveals Phase 3 Study for Continuous Carbidopa/Levodopa in Parkinson Disease
September 26th 2019The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.
Amantadine ER Capsules for Dyskinesia Show Consistent Safety, Improved Motor Skills
September 25th 2019Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.
Danielle Andrade, MD, MSc: Communicating and Network Building in Epilepsy Care
September 24th 2019The professor of medicine, neurology, at the University of Toronto shared insight into the importance of communication and a good network of physicians to an adult neurologist caring for patients with epilepsy.
Danielle Andrade, MD, MSc: Education for Adult Neurologists on Pediatric-Onset Epilepsies
September 19th 2019The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.
Jan Hillert, MD, PhD: The Blood-Brain Barrier in Multiple Sclerosis
September 19th 2019The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.
Achthar Gel Associated With Lower Cost Per Response in Multiple Sclerosis Relapse
September 18th 2019Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.
Danielle Andrade, MD, MSc: Ensuring Smooth Transitions to Adult Epilepsy Care
September 18th 2019The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.
R. Edward Hogan, MD: Clinician Takeaways for Using Diazepam Nasal Spray
September 17th 2019The director of the adult epilepsy center at Washington University in St. Louis discussed the takeaways for clinicians regarding the use of intranasal diazepam as a treatment for runs of seizures in patients with refractory epilepsy.
Jan Hillert, MD, PhD: Treating the Non-Inflammatory Aspects of MS
September 16th 2019The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the aspects of MS—such as brain volume loss—which are not currently being addressed by the available disease-modifying therapies.
Relapsing MS Treatment With Natalizumab Linked to High NEDA Rate Over 4 Years
September 16th 2019According to new data from STRIVE, 75.4% of those treated with natalizumab achieved overall No Evidence of Disease Activity status by year 4, and no patients had incidence of progressive multifocal leukoencephalopathy.
Ocrelizumab Is Beneficial Across Long-Term Multiple Sclerosis Outcomes
September 13th 2019The global head of neuroimmunology at Genentech spoke about the wealth of data being presented on its anti-CD20 monoclonal antibody ocrelizumab, as well as the success thus far in trials of its NMOSD agent, satralizumab.
Alberto Ascherio, MD, DrPH: Using Vitamin D to Treat MS
September 12th 2019The professor of epidemiology and nutrition at Harvard TH Chan School of Public Health discussed what might be an optimal dose of vitamin D supplementation in MS, and how vitamin D deficiency should be addressed as a modifiable risk factor.
Danielle Andrade, MD, MSc: Coordinating Epilepsy Care Transition Between Physicians
September 11th 2019The professor of medicine, neurology, at the University of Toronto discussed the need for physicians to work together while transitioning patients with epilepsy—who may have any number of comorbidities—from pediatric care to adult care.
Bruce Cree, MD, PhD, MAS: Exploring Clinical Utility of Siponimod, Fingolimod in MS
September 11th 2019The clinical research director of the UCSF Multiple Sclerosis Center discusses recent data on siponimod and its impact on cognitive measures in patients with secondary progressive MS, as well as results of the 3-arm ASSESS study comparing low-dose fingolimod and glatiramer acetate.